The aim of this study is to compare histology activity index (HAI) scores in patients with HBeAg positive and HBeAg negative CHB to see if there is any difference in severity of liver injury between these two types of HBV. We did percutaneous liver biopsies of 77 CHB patients. Serum HBeAg status were assessed in all study subjects. Of them, 37.66% patients (29/77) had HBeAg positive HBV infection, while the rest 62.33% (48/77) had HBeAg negative HBV infection. 22/48 (27.78%) patients with HBeAg negative CHB had mild to moderate CH and 26/48 (72.22%) patients had minimal CH (HAI score 1-3) . In contrast, mild to moderate CH was seen in 19/29(72.23%) patients with HBeAg positive CHB. The study shows there is no correlation between the necro-inflammatory activity in the liver and HBeAg status in the serum in patients with CHB.
Introduction
Hepatitis B virus (HBV) is a double-stranded DNA virus that belongs to the family of hepadnaviruses. 1 HBV infects nearly 350 million people worldwide. 2 The clinical manifestations vary widely with asymptomatic acute viral B hepatitis on one end and hepatocellular carcinoma (HCC) on the other end of the spectrum. There are about 400 million HBV careers worldwide. Of them 75-80% reside in Asia and Western Pacific. HBV is responsible for over 1 million deaths per year globally. It is a major cause of cirrhosis of liver and HCC worldwide. 1 HBV is mainly transmitted by percutaneous and membrane exposure to infected body fluids. HBsAg and HBV DNA by PCR have been identified in most body secretions e.g. blood, saliva, menstrual and vaginal discharges, seminal fluid and serous discharges with the exception of stool. 1 HBV replicates in hepatocytes, but HBV encoded proteins have been identified in other body tissues like testes, stomach, colon, kidney, bone marrow, peripheral mononuclear cells, nerve ganglia and skin, which represent large extra-hepatic reservoir of HBV. 3 HBV is transmitted from infected mother to neonate in or around the time of birth. 60-90% babies born to HBeAg positive mothers and 15-20% born to HBeAg negative mothers become infected respectively. There is also risk of transmission of HBV if the pregnant mother has acute viral B hepatitis in second or third trimester or within two months of labour. HBV has been detected in breast milk, but it is probably not transmitted through breast milk. 3
The precore/core region of the HBV genome encodes the nucleocapsid protein (HBcAg) and HBeAg. 4, 5 The core open reading frame has two transcripts with heterogeneous 5 ends and two in-phase initiation codons. HBeAg is translated from the precore mRNA producing a precursor polypeptide comprising the precore and the entire core region. The precore polypeptide is translocated into the endoplasmic reticulum by a signal peptide. Cleavage of the amino and carboxy termini results in a secretory protein HBeAg. HBcAg is translated from the pregenomic RNA.
The biological role of HBeAg in the HBV replication cycle is uncertain. Expression of HBeAg is nonessential for virus replication in animal models 6 and in humans. 7 It has been suggested that HBeAg may act as a tolerogen or a target for immune response. In utero exposure to HBeAg can induce immune tolerance in newborn mice. 8 Perinatal transmission of HBV from HBeAg-positive mothers results in chronic HBV infection in the majority of babies. 9 In addition, HBeAg appears to modulate the host's immune respons. 10, 13 Precore variants that do not produce HBeAg may be selected because they can evade immune clearance. Mutations in the precore region of the HBV genome have been described. 14, 18 It results in HBeAg negative HBV infection. 19, 23 The aim of this study is to compare the histological activity in liver due to chronic hepatitis B in patients with HBeAg positive and HBeAg negative CHB to see if there is any difference in severity of liver injury between these two types of HBV.
Methods
Patients with chronic HBV infection (HBsAg positive for at least 6 months) attending hepatology OPDs in BSMMU, Dhaka, Bangladesh between March 2008 and December 2008 were studied prospectively. Written informed consent was obtained from each patient. The patients had to be negative for anti-HCV antibody and positive for serum HBV DNA (>1 × 105 copies/ml) using a DNA hybridization assay (Digene Hydrid Capture 2 system; Digene Corporation, Gaithersburg, Maryland, USA); they were enrolled irrespective of their HBeAg status and liver enzyme levels. Patients with clinical evidence of liver cirrhosis were excluded.
All patients underwent percutaneous liver biopsy. Biopsies were done using trucut biopsy needle under local anaesthesia. The present study was carried out at the Department of Pathology, Bangabandhu Sheikh Mujib Medical University, Dhaka, from March 2008 to December 2008, to evaluate the histopathological changes in liver biopsies in HBsAg-positive chronic hepatitis patients. The aim of this study was to see the relationship between serum HBeAg status, and liver histology for the proper diagnosis and management of chronic hepatitis B patients. Out of seventy seven patients 29 patients were HBeAg positive and 48 case were HBeAg negative. Liver tissue were examined histologically to evaluate the features of chronic hepatitis and the intensity of necroinflammatory activity and fibrosis were scored by Knodell scoring system.
Results
Results are presented in a tabulated and figure forms. A total of 77 patients were studied. Results show that in HBeAg positive CHB HAI score (i.e. necro-inflammatory score) was between 1-3 in 10/29 patients, between 4-8 in 17/29patients, between 9-12 in 2/29 patients and no patients had score between 13-18. In HBeAg negative CHB, these figures are 26/48, 17/48, 5/48 respectively. 34.48% HBeAg CHB patients included in this study had minimal chronic hepatitis, 58.62% had mild chronic hepatitis and 6.89% had moderate chronic hepatitis. In HBeAg negative CHB patients, these figures were 54.16%, 50%, 35.41% and 10.41% respectively.
There was no histological diagnosis of marked chronic hepatitis in any group. 
Discussion
Our study reveals that patients with HBeAg negative CHB tend to develop more severe necro-inflammation and fibrosis in the liver compared to those who are HBeAg positive.
In 2004 In conclusion our study shows that there is no correlation between necro-inflammation and serum HBeAg status in patients with chronic hepatitis B infection. Our finding is not consistent with similar studies carried out elsewhere including those of Bangladesh. Since there is no significant correlation among serum HBeAg and liver histology of CHB, assessment of liver enzymes, histopathology and viral load all together are recommended to select the patients who need treatment.
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